Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HS-10519
- Development stage
- Unknown
- Lead developer
- Jiangsu Hengrui Medicine
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
HS-10519 is an investigational therapeutic being developed by Jiangsu Hengrui Medicine for the treatment of major depressive disorder (MDD) accompanied by acute suicidal ideation or behavior. It is administered as an injection and is currently being evaluated in Phase I/II clinical trials in China. The drug is typically studied as an adjunctive therapy to standard-of-care antidepressants such as SSRIs or SNRIs. While the specific molecular target has not been widely disclosed in public literature, its clinical positioning for rapid reduction of suicidal symptoms in MDD suggests it may target pathways involved in rapid-acting antidepressant effects, similar to NMDA receptor modulators.
Beyond the preview
Go deeper on HS-10519.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HS-10519.